Company intelligence / Profile preview

nailKALM

Sydney, New South Wales, Australia

Ownership: Private
Development stage: Other

Overview

nailKALM is a healthcare company focused on the treatment of fungal nail infections (onychomycosis) using a proprietary bioactive ingredient called AMYCOT. AMYCOT is derived from a specific strain of Arthrospira maxima (Spirulina) and works by inhibiting the growth of dermatophytes that cause nail and skin infections. The company's lead product is a topical lotion clinically proven to improve nail appearance and health without the side effects often associated with systemic antifungal medications. nailKALM positions itself at the intersection of natural bioactive research and dermatological clinical efficacy.

Therapeutic areas: Infectious DiseasesDermatology
Modalities: BiologicTopical
Industry: Biotech

Partnerships

AFT Pharmaceuticals

Beyond the preview

Go deeper on nailKALM.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nailKALM.

Explore the full profile